Immunotherapy a groundbreaking new cancer treatment, but prohibitively expensive

Original article by Tracy Bowden
abc.net au – Page: Online : 10-Sep-19

Developed by Swiss company Novartis, Kymriah is an innovative immunotherapy treatment that has been described by University of NSW cancer biologist Darren Saunders as a type of living drug. Saunders notes it has shown to be very beneficial for a large number of people with certain types of leukaemia and lymphoma, but not all patients. Dave Roberts, who has a type of lymphoma, says his doctor has told him that Kymriah is basically his only hope of survival. The federal government is not yet funding Kymriah for people with the type of cancer that Roberts has, so treatment would cost him $500,000.

CORPORATES
NOVARTIS AG, UNIVERSITY OF NEW SOUTH WALES

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s